Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Chemotherapy in Treating Patients With Breast Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Chemotherapy in Treating Patients With Breast Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Chemotherapy in Treating Patients With Breast Cancer Clinical research trials and Chemotherapy in Treating Patients With Breast Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Chemotherapy in Treating Patients With Breast Cancer. Chemotherapy in Treating Patients With Breast Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Chemotherapy in Treating Patients With Breast Cancer clinical trial. Human subjects often get the best healthcare possible for their Chemotherapy in Treating Patients With Breast Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "C" Clinical Trials Conditions > Chemotherapy in Treating Patients With Breast Cancer

Chemotherapy in Treating Patients With Breast Cancer



Chemotherapy in Treating Patients With Breast Cancer

For Condition: stage 3B breast cancer,Male Breast Cancer,stage 4 breast cancer,recurrent breast cancer,stage 3A breast cancer
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Kaplan Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of annamycin liposomal in treating patients who have locally advanced or metastatic breast cancer that has not responded to previous chemotherapy.
Details: OBJECTIVES: I. Determine the observed anti-tumor activity of annamycin liposomal in patients with anthracycline-resistant locally advanced or metastatic breast cancer. II. Determine the qualitative and quantitative toxicity and reversibility of toxicity of this regimen in these patients. III. Determine the clinical pharmacology of this regimen in these patients. IV. Determine the rationale for the dose and chosen schedule of this regimen in these patients. PROTOCOL OUTLINE: Patients receive annamycin liposomal IV over 60 minutes on day 1. Treatment continues every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 7-30 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of locally advanced or metastatic breast cancer - High likelihood of anthracycline resistance due to prior anthracycline exposure in the adjuvant or metastatic setting; Prior anthraquinone (e.g., mitoxantrone) insufficient; Prior cumulative anthracycline dose limited to doxorubicin-equivalent 350 mg/m2 by IV bolus or 450 mg/m2 by prolonged (at least 48 hours) infusion - Measurable or evaluable disease - Brain metastases treated by prior surgery and/or radiotherapy allowed if neurologic status stable 2 weeks after discontinuation of dexamethasone - Hormone receptor status: Not specified --Prior/Concurrent Therapy-- - Biologic therapy: No concurrent prophylactic filgrastim (G-CSF) - Chemotherapy: See Disease Characteristics; At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea) and recovered - Endocrine therapy: See Disease Characteristics - Radiotherapy: See Disease Characteristics; At least 3 weeks since prior radiotherapy and recovered - Surgery: See Disease Characteristics --Patient Characteristics-- - Age: 18 and over - Sex: Male or female - Menopausal status: Not specified - Performance status: Zubrod 0-2 - Life expectancy: At least 12 weeks - Hematopoietic: Absolute granulocyte count greater than 1,500/mm3; Platelet count greater than 100,000/mm3 - Hepatic: Bilirubin no greater than 1.5 mg/dL - Renal: Creatinine no greater than 1.5 mg/dL - Cardiovascular: No history of heart failure; Ejection fraction at least 55% by 2-dimensional echocardiogram - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; Other prior malignancy allowed if curatively treated and there is clear diagnosis of metastatic breast cancer requiring treatment
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
MatthewVolm,  Study Chair,  Kaplan Cancer Center

NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York City,  New York,  10016
United States
 


Additional Information:
Study ID Numbers:  CDR0000068486;  NCI-G01-1914,NYU-9851
Study Start Date: September 1998
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00012129

Other Stage 4 Breast Cancer Studies:
1. Chemotherapy in Treating Patients With Breast Cancer

2. Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast

3. Combination Chemotherapy Followed by Radiation Therapy With or Without Surgery in Treating Women With Locally Advanced or Inflammatory Breast Cancer

4. Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

5. Docetaxel With or Without Bevacizumab Followed by Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Locally Advanced Breast Cancer

Related Studies:

Other stage 4 breast cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Chemotherapy in Treating Patients With Breast Cancer
Modify your Search

  Other stage 4 breast cancer Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103